Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMicroba Life Sciences Ltd

Microba Life Sciences Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.035 AUD 0.00(0%)
Last update at 2026-11-12T04:34:00Z
VOLUME
61649
Market Cap
27.48M

Momentum Score

…

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.03
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Microba Life Sciences is an Australian diagnostics and services company that uses metagenomic sequencing and bioinformatics to analyze the human gut microbiome for clinical and research clients. Long-term growth may be supported by rising interest in microbiome-based diagnostics and therapeutics, expanding research and commercial partnerships, and greater demand for precision-health data. Investors may find it attractive because the company appears positioned with proprietary sequencing and analytics and a growing data asset that could underpin service and collaboration revenue.
Material investment risks include the need for robust clinical validation, regulatory and reimbursement uncertainty, competition from larger diagnostics and biotech firms, and potential financing and execution challenges during scale-up.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
14.76M
Revenue Per Share
0.03
Gross Profit TTM
7.03M
Debt / Equity
0.17
ROE
-72.87%
Net Debt
-3.84M
ROCE
-70.94%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -22.09M -15.05M -19.99M -12.67M -11.46M
Net income -20.72M -14.94M -19.94M -12.68M -11.47M
Selling general administrative - 16.95M 12.18M 9.64M 8.57M
Selling and marketing expenses - 0.66M 0.79M - 0.54M
Gross profit -11.74M 7.44M 5.91M 2.68M 2.37M
Reconciled depreciation - 4.43M 2.87M 1.64M 1.54M
Ebit -20.30M -14.94M -19.97M -20.23M -11.45M
Ebitda -15.89M -10.51M -17.10M -11.02M -9.91M
Depreciation and amortization 4.41M 4.43M 2.87M - 1.54M
Operating income -20.30M -24.61M -26.84M -12.68M -11.45M
Other operating expenses 35.06M 40.28M 38.93M 2.29M 20.96M
Interest expense 0.24M 0.18M 0.07M 1.19M 0.01M
Tax provision - -0.11M -0.05M 0.01M 0.01M
Interest income - 0.58M 1.00M 0.88M 0.05M
Net interest income - 0.41M 0.94M 0.82M -0.01M
Income tax expense -1.37M -0.11M -0.05M 0.01M 0.01M
Total revenue 14.76M 15.67M 12.09M 5.42M 4.69M
Total operating expenses 8.57M 32.05M 32.75M - 18.64M
Cost of revenue 26.50M 8.23M 6.18M 2.74M 2.32M
Total other income expense net -1.78M 9.56M 6.85M 6.74M 4.82M
Net income from continuing ops - -14.94M -19.94M -12.68M -11.47M
Net income applicable to common shares - -14.94M -19.94M -12.68M -11.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 39.81M 47.44M 58.04M 46.95M 39.48M
Intangible assets 14.14M 14.54M - 2.85M 0.85M
Other current assets 0.52M 0.33M 1.01M 1.14M 0.20M
Total liab 13.70M 14.94M 16.37M 8.38M 5.94M
Total stockholder equity 24.38M 32.49M 41.22M 38.57M 33.54M
Deferred long term liab - - - 2.66M 0.64M
Other current liab 3.35M 1.99M 5.28M 2.22M 3.61M
Common stock 120.46M - 102.88M 80.37M 62.88M
Capital stock - 108.54M - 80.37M 62.88M
Retained earnings -99.48M -78.76M -63.82M -43.88M -31.20M
Other liab - - - 0.32M 0.19M
Good will 9.20M 10.02M - - -
Other assets - - 0.00M 2.66M 0.64M
Cash 7.95M 11.74M 20.89M 18.68M 30.58M
Cash and equivalents - - - 12.43M 0.20M
Total current liabilities 11.19M 10.17M 12.37M 7.82M 5.26M
Current deferred revenue 1.88M - 2.18M - 2.55M
Net debt -3.84M - -19.31M - -29.26M
Short term debt 3.31M - 1.21M 0.00M 0.84M
Short long term debt - 0.75M - 0.36M 0.36M
Short long term debt total 4.11M - 1.58M - 1.33M
Other stockholder equity - - - 2.08M 0.08M
Property plant equipment - - - 2.58M 2.81M
Total current assets 13.89M 19.00M 32.25M 41.53M 35.82M
Net tangible assets - - - 38.39M 33.33M
Net receivables 3.21M 0.46M 8.10M 7.24M 3.42M
Long term debt - 0.47M - - -
Inventory 2.22M 1.94M 2.24M 0.64M 0.36M
Accounts payable 2.64M 2.35M 3.70M 2.98M 0.81M
Accumulated other comprehensive income 3.40M - 2.16M - 1.85M
Non currrent assets other 0.26M - 21.88M - -
Non current assets total 25.92M 28.44M 25.79M 5.43M 3.66M
Capital lease obligations - 2.01M - 0.78M 0.96M
Long term debt total - - - 0.23M 0.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.83M -13.95M -3.00M -1.73M
Change to liabilities - - - 2.53M 1.14M
Total cashflows from investing activities -3.80M -2.83M -13.95M -3.00M -1.73M
Net borrowings - 0.82M 0.06M -0.55M -0.13M
Total cash from financing activities 12.76M 5.58M 18.39M 16.68M 29.22M
Change to operating activities - - - -0.06M 0.23M
Net income -20.72M -14.94M -19.94M -12.68M -11.47M
Change in cash -3.79M -9.15M -11.15M 1.46M 17.60M
Begin period cash flow 11.74M 20.89M 32.04M 30.58M 12.98M
End period cash flow 7.95M 11.74M 20.89M 32.04M 30.58M
Total cash from operating activities -12.37M -12.01M -15.57M -12.39M -10.45M
Issuance of capital stock - 6.05M 20.36M 17.83M 31.25M
Depreciation 4.41M - 2.87M 1.22M 1.15M
Other cashflows from investing activities - -2.57M -2.89M 0.04M 0.14M
Dividends paid - - - - -0.43M
Change to inventory -0.28M -0.26M -0.31M -0.28M 0.15M
Change to account receivables 0.78M 3.99M -0.01M -3.81M -1.77M
Sale purchase of stock - -0.38M -1.26M 17.83M -1.90M
Other cashflows from financing activities -0.94M -0.90M -0.77M -0.60M 0.09M
Change to netincome - - - 0.26M -0.27M
Capital expenditures 0.24M 2.90M 4.38M 0.55M 1.87M
Change in working capital 0.11M 3.35M 0.99M 3.53M 2.85M
Other non cash items 3.83M -15.36M 0.51M - -
Free cash flow -12.61M -14.91M -19.95M -15.43M -1.87M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MAP
Microba Life Sciences Ltd		 -
-%		 0.04 - - 1.86 1.13 1.60 -8.00
SHL
Sonic Healthcare Ltd		 0.09
0.45%		 19.92 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 -
-%		 1.70 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.01
0.30%		 3.33 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
2.86%		 0.54 - 29.24 0.26 2.08 0.94 10.14

Profile*

Microba Life Sciences Ltd

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

324 Queen Street, Brisbane, QLD, Australia, 4000

61 13 0097 4621

https://microba.com

Name Title Year Born
Dr. Luke Reid Chief Exec. Officer NA
Prof. Gene Tyson Co-Founder & Non-Exec. Director NA
Mr. James Heath CFO & Company Sec. NA
Prof. Philip Hugenholtz Co-Founder & Chair of Scientific Advisory Board NA
Mr. Yao Liu Chief Technology Officer NA
Prof. Lutz Krause Chief Scientific Officer NA
Mr. Drew Webb Chief Marketing Officer NA
Prof. Trent Munro Sr. VP of Therapeutics NA
Dr. Nicola Angel Head of Laboratory Operations NA
Mr. Bernie Woodcroft Sr. VP of Platform Solutions NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…